Jci_page_head_homepage_01 Jci_page_head_homepage_02
Louis J. Picker, Edward F. Reed-Inderbitzin, Shoko I. Hagen, John B. Edgar, Scott G. Hansen, Alfred Legasse, Shannon Planer, Michael Piatak, Jeffrey D. Lifson, Vernon C. Maino, Michael K. Axthelm, Francois Villinger
Published in Volume 116, Issue 6
J Clin Invest. 2006; 116(6):1514–1524 doi:10.1172/JCI27564
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 9
Short-term IL-15 therapy does not increase viral replication in either ART-treated or untreated RMs and influences proliferation of pathogen-specific T cells based on their TEM component.

(A and B) Plasma viral loads of untreated (A) or ART-treated (B), SIV-infected RMs are shown before, during, and after IL-15 therapy. (C) Cytokine flow cytometry was used to determine the pre-IL-15-treatment memory phenotype (CD28 versus CCR7) and follow the post-IL-15-treatment proliferative status (Ki-67 expression) of peripheral blood CD4+ and CD8+ memory T cells responsive to SIVgag or RhCMV in 3 SIV-infected animals previously shown to have IL-15–responsive total TEM cell populations (see Figure 8) — the 1 spontaneous controller (no. 21021) given 10 μg/kg, and 2 ART-treated RMs (nos. 21046 and 20955) given 50 μg/kg. Note that in all 3 RMs, CMV-specific CD4+ T cells included a large fraction of TEM cells and showed a marked in vivo proliferative response to IL-15; in contrast, SIVgag-specific CD4+ T cells included negligible TEM cells and little proliferative response to IL-15. Both SIVgag- and RhCMV-specific CD8+ T cells (in the 2 of 3 RMs that manifested such responses) included a large TEM component and manifested IL-15 responsiveness.